← Eichor
Condition: Antibody Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
Phase 1 · 2 location(s) · HTIC, Inc · NCT07449572Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05126472PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281National Registry of IgG4-RD in China
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT03023371Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg)
Phase 3 · 129 location(s) · Sanofi · NCT06290141A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch
Phase 1/Phase 2 · 23 location(s) · AbbVie · NCT06158854Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Phase 2 · 1 location(s) · Genethon · NCT06518005Predictive Signature of Benralizumab Response
Phase 4 · 20 location(s) · Nantes University Hospital · NCT04565483Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT07347769Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
Phase 2 · 4 location(s) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Ot · NCT06205602Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment
Phase N/A · 3 location(s) · Azienda Usl di Bologna · NCT06321588Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3 · 116 location(s) · The Lymphoma Academic Research Organisation · NCT06284122CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-ce
Phase N/A · 1 location(s) · Hospital Mutua de Terrassa · NCT07070596Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951Normalizing Antibody Detection in First-void Urine
Phase N/A · 1 location(s) · Universiteit Antwerpen · NCT06582654A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
Phase 2 · 5 location(s) · GlaxoSmithKline · NCT07224672V-IMMUNE® for Immune Thrombocytopenia
Phase 3 · 2 location(s) · On Pharma Importadora, Exportadora e Distribuidora de Medica · NCT06962631IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
Phase 2 · 1 location(s) · Endeavor Health · NCT04153422EWALL-PH OBSERVARTORY 2022
Phase N/A · 23 location(s) · Versailles Hospital · NCT07684131An Exploratory Study by Fast CAR T Cells
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06327997Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Shanghai Henlius Biotech · NCT07473726
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.